High-dose bevacizumab improves survival when combined with FOLFOX4 in previously treated advanced colorectal cancer: Results from the Eastern Cooperative Oncology Group (ECOG) study E3200. - Giantonio,B.J.; Catalano,P.J.; Meropol,N.J. (ASCO, 2005)